- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Spring 2015
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Forest Labs., LLC v. Apotex Corp., 15- 0018 (D. Del.) |
Jan. 5, 2015 | Hon. Gregory M. Sleet | Teflaro® (ceftaroline fosamil injection for intravenous) |
6,417,175
6,906,055
7,419,973
8,247,400
|
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00522 (PTAB) | Jan. 5, 2015 | N/A | INOmax® (nitric oxide) | 8,282,966 |
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00524 (PTAB) | Jan. 5, 2015 | N/A | INOmax ® (nitric oxide) | 8,293,284 |
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00525 (PTAB) | Jan. 5, 2015 | N/A | INOmax ® (nitric oxide) | 8,431,163 |
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00526 (PTAB) | Jan. 5, 2015 | N/A | INOmax ® (nitric oxide) | 8,795,741 |
| Praxair Distribution, Inc. v. iNO Therapeutics, Inc., IPR2015-00529 (PTAB) | Jan. 5, 2015 | N/A | INOmax ® (nitric oxide) | 8,846,112 |
| Iceutica Pty Ltd. v. Lupin Ltd., 15-0045 (D. Md.) | Jan. 7, 2015 | Hon. J. Frederick Motz | Zorvolex® (diclofenac capsules) | 8,679,544 |
| Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc., 15-0018 (M.D.N.C.) | Jan. 7, 2015 | Hon. N. C. Tilley, Jr. | Jevtana® Kit (cabazitaxel injection) | 5,847,170 |
| Pfizer Inc. v. Mylan Inc., 15-0026 (D. Del.) | Jan. 8, 2015 | Hon. Sue L. Robinson | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
|
| Salix Pharms., Inc. v. Novel Labs., Inc., 15-0027 (D. Del.) | Jan. 8, 2015 | Hon. Gregory M. Sleet | Apriso® (mesalamine capsules) | 8,865,688 |
| Otsuka Pharm. Co., Ltd. v. Hetero Drugs Ltd., 15-0161 (D.N.J.) | Jan. 8, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,580,796
8,642,760
8,759,350
|
| Jazz Pharms., Inc. v. Par Pharm, Inc., 15-0173 (D.N.J.) | Jan. 8, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,859,619 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-00545 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,589,182 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-00546 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,765,106 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-00547 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,765,107 |
| Par Pharm., Inc. v. Jazz Pharms., Inc., IPR2015-00548 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,895,059 |
| Teva Pharms. USA, Inc. v. ViiV Healthcare Co., IPR2015-00550 (PTAB) | Jan. 8, 2015 | N/A | Trizivir® (abacavir sulfate / lamivudine / zidovudine) | 6,417,191 |
| Par Pharm., Inc. v. Jazz Pharms., Inc., IPR2015-00551 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 8,457,988 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2015-00554 (PTAB) | Jan. 8, 2015 | N/A | Xyrem® (sodium oxybate oral solution) | 7,668,730 |
| Jazz Pharms., Inc. v. Ranbaxy Labs. Ltd., 15-0187 (D.N.J.) | Jan. 9, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 8,859,619 |
| Pfizer Inc. v. Mylan Inc., 15-0004 (N.D.W.V.) | Jan. 9, 2015 | Hon. Irene M. Keeley | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
|
| Horizon Pharma Ireland Ltd. v. Paddock Labs., LLC, 15-0368 (D.N.J.) | Jan. 13, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Johnson Matthey Inc. v. Pfizer, Inc., 15-0014 (E.D. Va.) | Jan. 13, 2015 | Hon. Arenda L. Wright Allen | Tikosyn® (dofetilide capsules) | 6,124,363 |
| Actelion Pharms Ltd. v. Icos Corp., IPR2015-00561 (PTAB) | Jan. 13, 2015 | N/A | Cialis® (tadalafil tablets) | 7,182,958 |
| Actelion Pharms Ltd. v. Icos Corp., IPR2015-00562 (PTAB) | Jan. 13, 2015 | N/A | Cialis® (tadalafil tablets) | 6,821,975 |
| Millennium Pharms., Inc. v. Hetero Labs Ltd., 15-0039 (D. Del.) | Jan. 14, 2015 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| Millennium Pharms., Inc. v. Onco Therapies Ltd., 15-0040 (D. Del.) | Jan. 14, 2015 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| Horizon Pharma Ireland Ltd. v. Paddock Labs., LLC, 15-0043 (D. Del.) | Jan. 14, 2015 | Hon. Sue L. Robinson | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharms. Ltd., 15-0280 (D.N.J.) | Jan. 14, 2015 | Hon. Stanley R. Chesler | Latuda® (lurasidone hydrochloride tablets) | 5,532,372 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Invagen Pharms., Inc., 15-0281 (D.N.J.) | Jan. 14, 2015 | Hon. Stanley R. Chesler | Latuda® (lurasidone hydrochloride tablets) | 5,532,372 |
| Alcon Labs., Inc. v. Akorn, Inc., 15-0285 (D.N.J.) | Jan. 14, 2015 | Hon. Madeline C. Arleo | Durezol® (difluprednate ophthalmic emulsion) | 6,114,319 |
| Sanofi-Aventis U.S. LLC v. Apotex Corp., 15-0287 (D.N.J.) | Jan. 14, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Sanofi-Aventis U.S. LLC v. Breckenridge Pharm., Inc., 15-0289 (D.N.J.) | Jan. 14, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Sanofi-Aventis U.S. LLC v. Onco Therapies Ltd., 15-0290 (D.N.J.) | Jan. 14, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Sanofi-Aventis U.S. LLC v. Apotex Corp., 15-0044 (D. Del.) | Jan. 15, 2015 | Hon. Leonard P. Stark | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Sanofi-Aventis U.S. LLC v. Breckenridge Pharm., Inc., 15-80056 (S.D. Fla.) | Jan. 15, 2015 | Hon. Donald M. Middlebrooks | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Laboratoire HRA Pharma v. Teva Pharms. USA, Inc., 15-0045 (D. Del.) | Jan. 16, 2015 | Hon. Richard G. Andrews | Ella® (ulipristal acetate oral tablets) |
8,426,392
8,512,745
8,735,380
|
| Boehringer Ingelheim GmbH & Co. KG v. Teva Pharms. USA, Inc., 15-0048 (D. Del.) | Jan. 16, 2015 | Hon. Sue L. Robinson | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Shionogi & Co., Ltd. v. Aurobindo Pharma Ltd., 15-0319 (D.N.J.) | Jan. 16, 2015 | Hon. Michael A. Shipp | Doribax® (doripenem for injection) | 8,247,402 |
| Supernus Pharms., Inc. v. Par Pharm. Cos., Inc., 15-0326 (D.N.J.) | Jan. 16, 2015 | Hon. Susan D. Wigenton | Trokendi XR® (topiramate extended-release capsules) |
8,298,576
8,298,580
8,663,683
8,877,248
|
| Senju Pharm. Co., Ltd. v. Lupin, Ltd., 15-0335 (D.N.J.) | Jan. 16, 2015 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,871,813
8,927,606
|
| Senju Pharm. Co., Ltd. v. Apotex Inc., 15-0336 (D.N.J.) | Jan. 16, 2015 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
|
| Senju Pharm. Co., Ltd. v. Paddock Labs., LLC, 15-0337 (D.N.J.) | Jan. 16, 2015 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
|
| Supernus Pharms., Inc. v. TWi Pharms., Inc., 15-0369 (D.N.J.) | Jan. 16, 2015 | Hon. Renee Marie Bumb | Oxtellar XR® (oxcarbazepine extended-release tablets) |
7,722,898
7,910,131
8,617,600
8,821,930
|
| Shionogi & Co., Ltd. v. Aurobindo Pharma Ltd., 15-0478 (N.D. Ill.) | Jan. 16, 2015 | Hon. Robert W. Gettleman | Doribax® (doripenem for injection) | 8,247,402 |
| Teva Pharms. USA, Inc. v. AstraZeneca Pharms. LP, 15-0050 (D. Del.) | Jan. 19, 2015 | Hon. Gregory M. Sleet | Byetta® (exenatide injection) |
7,297,761
7,741,269
|
| Tris Pharma Inc. v. Par Pharm., Inc., 15-0068 (D. Del.) | Jan. 21, 2015 | Hon. Gregory M. Sleet |
Quillivant XR® (methylphenidate hydrochloride
extended-release oral suspension)
|
8,062,667
8,287,903
8,465,765
8,563,033
8,778,390
|
| Boehringer Ingelheim GmbH & Co. KG v. Mylan Pharms. Inc., 15-0010 (N.D.W.V.) | Jan. 21, 2015 | Hon. Irene M. Keeley | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Teva Pharms. USA, Inc. v. Dr. Reddy’s Labs., Ltd., 15-0471 (D.N.J.) | Jan. 22, 2015 | Hon. Claire C. Cecchi | Copaxone® (glatiramer acetate for injection) | 5,800,808 |
| Teva Pharms. USA, Inc. v. Synthon Pharms., Inc., 15-0472 (D.N.J.) | Jan. 22, 2015 | Hon. Claire C. Cecchi | Copaxone® (glatiramer acetate for injection) | 5,800,808 |
| Acorda Therapeutics, Inc. v. Actavis Labs. FL, Inc., 15-0077 (D. Del.) | Jan. 23, 2015 | Hon. Leonard P. Stark | Ampyra® (dalfampridine extended-release tablets) | 5,540,938 |
| Novartis Pharms. Corp. v. Par Pharm., Inc., 15-0078 (D. Del.) | Jan. 23, 2015 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
5,665,772
7,297,703
7,741,338
|
| Pfizer Inc. v. Mylan Pharms. Inc., 15-0079 (D. Del.) | Jan. 23, 2015 | Hon. Gregory M. Sleet | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
| Astellas Pharma Inc. v. Fresenius Kabi USA, LLC, 15-0080 (D. Del.) | Jan. 23, 2015 | Hon. Leonard P. Stark | Mycamine® (micafungin sodium for injection) |
6,107,458
6,774,104
|
| Eli Lilly and Co. v. Fresenius Kabi USA, LLC, 15-0096 (S.D. Ind.) | Jan. 23, 2015 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed disodium for intravenous infusion) | 7,772,209 |
| Spectrum Pharms., Inc. v. Amneal Pharms. LLC, 15-0139 (D. Nev.) | Jan. 23, 2015 | Hon. James C. Mahan | Fusilev® (levoleucovorin calcium for injection) | 6,500,829 |
| Senju Pharm. Co., Ltd. v. Paddock Labs., LLC, 15-0087 (D. Del.) | Jan. 26, 2015 | Hon. Sue L. Robinson | Prolensa® (bromfenac ophthalmic solution) |
8,129,431
8,669,290
8,754,131
8,871,813
8,927,606
|
| AstraZeneca Pharms. LP v. Glenmark Pharms. Ltd., 15-0615 (D.N.J.) | Jan. 26, 2015 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Pfizer Inc. v. Mylan Pharms. Inc., 15-0013 (N.D.W.V.) | Jan. 27, 2015 | Hon. Irene M. Keeley | Toviaz® (fesoterodine fumarate extended-release tablets) |
6,858,650
7,384,980
7,855,230
7,985,772
8,338,478
|
| Otsuka Pharm. Co., Ltd. v. Apotex Inc., 15-0109 (D. Del.) | Jan. 29, 2015 | Hon. Richard G. Andrews | Samsca® (tolvaptan tablets) |
5,753,677
8,501,730
|
| Bayer Healthcare LLC v. Mylan Pharms. Inc., 15-0114 (D. Del.) | Jan. 30, 2015 | Hon. Leonard P. Stark | Nexavar® (sorafenib tosylate tablets) |
8,618,141
8,877,933
|
| Shionogi & Co., Ltd. v. Apotex Corp., 15-0668 (D.N.J.) | Jan. 30, 2015 | Hon. Peter G. Sheridan | Doribax® (doripenem for injection) | 8,247,402 |
| Celgene Corp. v. Lannett Holdings, Inc., 15-0697 (D.N.J.) | Jan. 30, 2015 | Hon. Susan D. Wigenton | Thalomid® (thalidomide capsules) |
6,045,501
6,315,720
6,561,976
6,561,977
6,755,784
6,869,399
7,141,018
7,230,012
7,435,745
7,874,984
7,959,566
8,204,763
8,315,886
8,589,188
8,626,531
|
| Cosmo Technologies Ltd. v. Par Pharm., Inc., 15-0116 (D. Del.) | Feb. 2, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
7,431,943
8,293,273
8,784,888
8,895,064
RE43,799
|
| Cephalon, Inc. v. Unimark Remedies Ltd., 15-0117 (D. Del.) | Feb. 2, 2015 | Hon. Gregory M. Sleet | Nuvigil® (armodafinil tablets) | 7,132,570 |
| Sanofi-Aventis U.S. LLC v. Actavis LLC, 15-0776 (D.N.J.) | Feb. 2, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) |
5,847,170
7,241,907
|
| Teva Pharms. USA, Inc. v. Amneal Pharms. LLC, 15-0124 (D. Del.) | Feb. 3, 2015 | Hon. Gregory M. Sleet | Copaxone® (glatiramer acetate for injection) |
8,232,250
8,399,413
|
| Mylan Pharms. Inc. v. Warner-Chilcott Co. LLC, IPR2015-00682 (PTAB) | Feb. 3, 2015 | N/A |
Lo Loestrin® Fe
(ethinyl estradiol / norethindrone acetate tablets)
|
7,704,984 |
| Orexo AB v. Actavis Labs. FL, Inc., 15-0826 (D.N.J.) | Feb. 4, 2015 | Hon. Peter G. Sheridan | Abstral® (fentanyl sublingual tablets) |
6,759,059
6,761,910
7,910,132
|
| AstraZeneca AB v. Perrigo Co. PLC, 15-1057 (D.N.J.) | Feb. 4, 2015 | Hon. Mary L. Cooper |
Nexium 24HR®
(esomeprazole magnesium delayed-release capsules)
|
6,369,085
7,411,070
|
| Novartis Pharms. Corp. v. Roxane Labs., Inc., 15-0128 (D. Del.) | Feb. 5, 2015 | Hon. Richard G. Andrews | Afinitor® (everolimus tablets) |
5,665,772
7,297,703
7,741,338
|
| Novartis Pharms. Corp. v. BPI Labs LLC, 15-0950 (D.N.J.) | Feb. 5, 2015 | Hon. Susan D. Wigenton | Zometa® (zoledronic acid for injection) | 8,324,189 |
| Jazz Pharms., Inc. v. Amneal Pharms., LLC, 15-1043 (D.N.J.) | Feb. 6, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
8,731,963
8,772,306
8,859,619
|
| Dr. Reddy’s Labs., Inc. v. Fresenius Kabi USA, LLC, IPR2015-00715 (PTAB) | Feb. 6, 2015 | N/A | Diprivan® (propofol injectable) | 8,476,010 |
| Mylan Pharms. Inc. v. Yeda Research & Development Co. Ltd., IPR2015-00644 (PTAB) | Feb. 7, 2015 | N/A | Copaxone® (glatiramer acetate for injection) | 8,399,413 |
| Novartis Pharms. Corp. v. BPI Labs, LLC, 15-0272 (M.D. Fla.) | Feb. 9, 2015 | Hon. Susan C Bucklew | Zometa® (zoledronic acid for injection) | 8,324,189 |
| Roxane Labs., Inc. v. Lupin Ltd., 15-1095 (D.N.J.) | Feb. 10, 2015 | Hon. Stanley R. Chesler | PhosLo® GelCaps (calcium acetate capsules) | 8,563,032 |
| Novartis AG v. Ezra Ventures, LLC, 15-0150 (D. Del.) | Feb. 11, 2015 | Hon. Leonard P. Stark | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Novartis AG v. HEC Pharm Co., Ltd., 15-0151 (D. Del.) | Feb. 11, 2015 | Hon. Leonard P. Stark | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Novo Nordisk Inc. v. Sun Pharm. Indus. Ltd., 15-1287 (D.N.J.) | Feb. 12, 2015 | Hon. Michael A. Shipp | Vagifem® (estradiol tablets) | 7,018,992 |
| Forest Labs., LLC v. Alembic Pharms. Ltd., 15-0158 (D. Del.) | Feb. 13, 2015 | Hon. Sue L. Robinson | Saphris® (asenapine maleate tablets) | 5,763,476 |
| AbbVie, Inc. v. Mylan Pharms. Inc., 15-1402 (N.D. Ill.) | Feb. 13, 2015 | Hon. Robert W. Gettleman | Kaletra® (lopinavir / ritonavir tablets) |
8,025,899
8,268,349
8,309,613
8,377,952
8,399,015
8,470,347
8,691,878
|
| Helsinn Healthcare S.A. v. Gavis Pharma LLC, 15-1228 (D.N.J.) | Feb. 13, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Novartis AG v. Ezra Ventures, LLC, 15-0095 (E.D. Ark.) | Feb. 13, 2015 | Hon. Kristine G. Baker | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 15-0164 (D. Del.) | Feb. 17, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
7,431,943
8,293,273
8,784,888
8,895,064
RE43,799
|
| INO Therapeutics LLC v. Praxair Distribution, Inc., 15-170 (D. Del.) | Feb. 19, 2015 | Hon. Gregory M. Sleet | INOmax® (nitric oxide for inhalation) |
8,282,966
8,293,284
8,431,163
8,795,741
8,846,112
8,291,904
8,573,210
8,573,209
8,776,794
8,776,795
|
| Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 15-1312 (D.N.J.) | Feb. 19, 2015 | Hon. Madeline C. Arleo | Uceris® (budesonide tablets) |
7,410,651
7,431,943
8,293,273
8,784,888
8,895,064
RE43,799
|
| Ferring Pharms. Inc. v. Par Pharm., Inc., 15-0173 (D. Del.) | Feb. 20, 2015 | Hon. Richard G. Andrews |
Prepopik®
(sodium picosulfate / magnesium oxide / citric acid solution)
|
8,450,338
8,481,083
|
| Fresenius Medical Care Holdings, Inc. v. Novel Labs., Inc., 15-10472 (D. Mass.) | Feb. 20, 2015 | Hon. Richard G. Stearns | PhosLo® GelCaps (calcium acetate) |
6,576,665
6,875,445
|
| Jazz Pharms., Inc. v. Roxane Labs., Inc., 15-1360 (D.N.J.) | Feb. 20, 2015 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) |
8,461,203
8,772,306
8,859,619
|
| Fresenius Medical Care Holdings, Inc. v. Novel Labs., Inc., 15-1361 (D.N.J.) | Feb. 20, 2015 | Hon. Peter G. Sheridan | PhosLo® GelCaps (calcium acetate) |
6,576,665
6,875,445
|
| Cephalon, Inc. v. Sandoz Inc., 15-0178 (D. Del.) | Feb. 23, 2015 | Hon. Gregory M. Sleet | Treanda® (bendamustine hydrochloride for infusion) |
8,669,279
8,883,836
8,895,756
|
| Cephalon, Inc. v. Dr. Reddy’s Labs., Ltd., 15-0179 (D. Del.) | Feb. 23, 2015 | Hon. Gregory M. Sleet | Treanda® (bendamustine hydrochloride for infusion) |
8,669,279
8,883,836
8,895,756
|
| Shire LLC v. Par Pharm., Inc., 15-1454 (D.N.J.) | Feb. 26, 2015 | Hon. Renee Marie Bumb |
Adderall XR® (dextroamphetamine sulfate /
dextroamphetamine saccharate /
amphetamine aspartate monohydrate /
amphetamine sulfate tablets)
|
RE42,096
RE41,148
|
| Purdue Pharma L.P. v. Actavis Labs. UT, Inc., 15-0192 (D. Del.) | Feb. 27, 2015 | Hon. Sue L. Robinson | Butrans® (buprenorphine transdermal system) |
RE41,408
RE41,489
RE41,571
|
| Cosmo Technologies Ltd. v. Alvogen Pine Brook, Inc., 15-0193 (D. Del.) | Feb. 27, 2015 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
8,784,888
RE43,799
|
| AstraZeneca Pharms. LP v. Macleods Pharms., Ltd., 15-1513 (D.N.J.) | Feb. 27, 2015 | Hon. Claire C. Cecchi |
Seroquel XR®
(quetiapine fumarate extended-release tablets)
|
5,948,437 |
| Coalition for Affordable Drugs (ADROCA) LLC v. Acorda Therapeutics, Inc., IPR2015-00817 (PTAB) | Feb. 27, 2015 | N/A | Ampyra® (dalfampridine extended-release tablets) | 8,007,826 |
| Otsuka Pharm. Co., Ltd. v. Amneal Pharms. LLC, 15-1585 (D.N.J.) | Mar. 2, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,759,350
|
| Mylan Pharms. Inc. v. Yeda Research & Development Co. Ltd., IPR2015-00830 (PTAB) | Mar. 3, 2015 | N/A |
Copaxone®
(glatiramer acetate for injection)
|
8,969,302 |
| Vivus, Inc. v. Actavis Labs. FL, Inc., 15-1636 (D.N.J.) | Mar. 4, 2015 | Hon. Stanley R. Chesler |
Qsymia® (phentermine /
topiramate extended-release capsules)
|
8,895,057
8,895,058
|
| Novartis AG v. HEC Pharm Co., Ltd., 15-1647 (D.N.J.) | Mar. 5, 2015 | Hon. Claire C. Cecchi | Gilenya® (fingolimod hydrochloride capsules) | 5,604,229 |
| Boehringer Ingelheim Pharma GMBH & Co. KG v. Breckenridge Pharm., Inc., 15-1662 (D.N.J.) | Mar. 5, 2015 | Hon. Mary L. Cooper | Pradaxa® (dabigatran etexilate mesylate capsules) | 6,087,380 |
| Baxter Healthcare Corp. v. Sagent Pharms. Inc., 15-1684 (D.N.J.) | Mar. 6, 2015 | Hon. Jerome B. Simandle |
Brevibloc®
(esmolol hydrochloride in sodium chloride solution)
|
6,310,094
6,528,540
|
| Otsuka Pharm. Co., Ltd. v. Wockhardt Bio AG, 15-1690 (D.N.J.) | Mar. 6, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,759,350
7,053,092
|
| Biomarin Pharm. Inc. v. Par Pharm., Inc., 15-1706 (D.N.J.) | Mar. 6, 2015 | Hon. Michael A. Shipp | Kuvan® (sapropterin dihydrochloride tablets) |
7,566,462
7,566,714
7,612,073
7,727,987
8,003,126
8,067,416
RE43,797
8,318,745
|
| Baxter Healthcare Corp. v. Sagent Pharms. Inc., 15-2076 (N.D. Ill.) | Mar. 9, 2015 | Hon. Richard A. Posner |
Brevibloc®
(esmolol hydrochloride in sodium chloride solution)
|
6,310,094
6,528,540
|
| Otsuka Pharm. Co., Ltd. v. Sandoz Inc., 15-1716 (D.N.J.) | Mar. 9, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,759,350
|
| Allergan Sales, LLC v. Sandoz, Inc., 15-0347 (E.D. Tex.) | Mar. 9, 2015 | Hon. Rodney Gilstrap |
Combigan® (brimonidine tartrate /
timolol maleate ophthalmic solution)
|
7,030,149
7,320,976
7,642,258
8,748,425
|
| Ferrum Ferro Capital, LLC v. Allergan Sales, LLC, IPR2015-00858 (PTAB) | Mar. 9, 2015 | N/A |
Combigan®
(brimonidine tartrate /
timolol maleate ophthalmic solution)
|
7,030,149 |
| Sanofi-Aventis U.S. LLC v. Apotex Corp., 15-1835 (D.N.J.) | Mar. 11, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 8,927,592 |
| Sanofi-Aventis U.S. LLC v. Breckenridge Pharm., Inc., 15-1836 (D.N.J.) | Mar. 11, 2015 | Hon. Michael A. Shipp | Jevtana® Kit (cabazitaxel injection) | 8,927,592 |
| Galderma Labs., L.P. v. Actavis Labs. UT, Inc., 15-0232 (D. Del.) | Mar. 12, 2015 | Hon. Leonard P. Stark | Mirvaso® (brimonidine topical gel) |
7,439,241
8,410,102
8,426,410
8,859,551
8,513,247
8,513,249
|
| Accord Healthcare Inc. v. Daiichi Sankyo Co., Ltd., IPR2015-00864 (PTAB) | Mar. 12, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,404,703 |
| Accord Healthcare Inc. v. Daiichi Sankyo Co., Ltd., IPR2015-00865 (PTAB) | Mar. 13, 2015 | N/A | Effient® (prasugrel hydrochloride tablets) | 8,569,325 |
| Apotex Inc. v. Wyeth LLC, IPR2015-00873 (PTAB) | Mar. 12, 2015 | N/A | Tygacil® (tigecycline injectable IV infusion) | 7,879,828 |
| Horizon Pharma Ireland Ltd. v. Taro Pharms. USA, Inc., 15-2046 (D.N.J.) | Mar. 13, 2015 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) |
8,217,078
8,252,838
8,546,450
8,563,613
8,618,164
8,871,809
|
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00884 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,291,904 |
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00888 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,776,794 |
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00889 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,573,209 |
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00891 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,573,210 |
| Praxair Distribution, Inc. v. iNO Therapeutics, LLC, IPR2015-00893 (PTAB) | Mar. 16, 2015 | N/A | INOmax® (nitric oxide) | 8,776,795 |
| Bristol-Myers Squibb Co. v. Mylan Pharms., Inc., 15-1949 (D.N.J.) | Mar. 17, 2015 | Hon. Freda L. Wolfson | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Otsuka Pharm. Co., Ltd. v. Indoco Remedies Ltd., 15-1967 (D.N.J.) | Mar. 17, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,759,350
|
| Bristol-Myers Squibb Co. v. Mylan Pharms., Inc., 15-0049 (N.D.W.V.) | Mar. 19, 2015 | Hon. Irene M. Keeley | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2015-00902 (PTAB) | Mar. 19, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,669,290 |
| Innopharma Licensing, Inc. v. Senju Pharm. Co., Ltd., IPR2015-00903 (PTAB) | Mar. 19, 2015 | N/A | Prolensa® (bromfenac ophthalmic solution) | 8,129,431 |
| Noven Pharms., Inc. v. Actavis Labs. UT, Inc., 15-0249 (D. Del.) | Mar. 20, 2015 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) | 8,231,906 |
| Merck Sharp & Dohme Corp. v. Amneal Pharms. LLC, 15-0250 (D. Del.) | Mar. 20, 2015 | Hon. Sue L. Robinson | Nasonex® (mometasone furoate monohydrate metered nasal spray) | 6,127,353 |
|
Boehringer Ingelheim Pharma GmbH & Co. KG v.
Breckenridge Pharm., Inc., 15-80377 (S.D. Fla.)
|
Mar. 20, 2015 | Hon. Kenneth A. Marra | Pradaxa® (dabigatran etexilate mesylate capsules)) | 6,087,380 |
| Helsinn Healthcare S.A. v. Hospira, Inc., 15-2077 (D.N.J.) | Mar. 23, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Helsinn Healthcare S.A. v. Par Pharm. Cos., Inc., 15-2078 (D.N.J.) | Mar. 23, 2015 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 15-0260 (D. Del.) | Mar. 24, 2015 | Hon. Sue L. Robinson | OxyContin® (oxycodone hydrochloride extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,652,497
|
| Helsinn Healthcare S.A. v. Hospira, Inc., 15-0264 (D. Del.) | Mar. 25, 2015 | Hon. Gregory M. Sleet | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Helsinn Healthcare S.A. v. Par Pharm. Cos., Inc., 15-0265 (D. Del.) | Mar. 25, 2015 | Hon. Gregory M. Sleet | Aloxi® (palonosetron hydrochloride IV solution) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 15-11294 (D. Mass.) | Mar. 26, 2015 | Hon. F. Dennis Saylor, IV | OxyContin® (oxycodone hydrochloride extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,652,497
|
| Reckitt Benckiser LLC v. Amneal Pharms LLC, 15-2155 (D.N.J.) | Mar. 26, 2015 | Hon. Claire C. Cecchi | Mucinex® (guaifenesin extended-release tablets) |
6,372,252
6,955,821
7,838,032
|
| Reckitt Benckiser LLC v. Perrigo Co., 15-2156 (D.N.J.) | Mar. 26, 2015 | Hon. Claire C. Cecchi | Mucinex® (guaifenesin extended-release tablets) |
6,372,252
6,955,821
7,838,032
|
| Novo Nordisk Inc. v. Baxter Healthcare Corp., 15-2157 (D.N.J.) | Mar. 26, 2015 | Hon. Peter G. Sheridan | Novoeight® (turoctocog alfa) |
6,100,061
6,475,725
6,936,441
7,094,574
8,080,414
8,084,251
8,084,252
8,329,465
|
| Forest Labs., LLC v. Accord Healthcare Inc., 15-0272 (D. Del.) | Mar. 27, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| Forest Labs., LLC v. Alembic Pharms. Ltd., 15-0273 (D. Del.) | Mar. 27, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| Forest Labs., LLC v. Apotex Inc., 15-0274 (D. Del.) | Mar. 27, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| Forest Labs., LLC v. Teva Pharms. USA, Inc., 15-0275 (D. Del.) | Mar. 27, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
| McNeil-PPC, Inc. v. Watson Labs., Inc., 15-2197 (D.N.J.) | Mar. 27, 2015 | Hon. Madeline C. Arleo | Rogaine® (5% minoxidil topical aerosol foam) | 6,946,120 |
| Forest Labs., LLC v. Invagen Pharms. Inc., 15-0277 (D. Del.) | Mar. 30, 2015 | Hon. Gregory M. Sleet | Viibryd® (vilazodone tabletsa) |
7,834,020
8,193,195
8,236,804
8,673,921
|
GENERICally Speaking Spring 2015
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.